Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Patisiran: Product Stability
Standard response letter on patisiran and product stability. The letter includes information on the chemical, physical and photostability of the active substance, patisiran, and the diluted patisiran solution.
Standard response letter on patisiran and product stability. The letter includes information on the chemical, physical and photostability of the active substance, patisiran, and the diluted patisiran solution.
Patisiran & Vutrisiran: Chemical and Molecular Differences
Standard response letter on the differences between the chemistries of patisiran and vutrisiran.
Standard response letter on the differences between the chemistries of patisiran and vutrisiran.
Lumasiran: Dialysis
Standard response letter on lumasiran and dialysis. This medical information response contains clinical data from the ILLUMINATE-C study and published case reports.
Standard response letter on lumasiran and dialysis. This medical information response contains clinical data from the ILLUMINATE-C study and published case reports.
Vutrisiran: Transitioning from TTR Stabilizers (Tafamidis or Diflunisal)
Standard response letter on the transition from TTR stabilizers (tafamidis or diflunisal) to vutrisiran.
Standard response letter on the transition from TTR stabilizers (tafamidis or diflunisal) to vutrisiran.
Patisiran: Filters for Preparation and Infusion
Standard response letter on filters used for the preparation and infusion of patisiran.
Standard response letter on filters used for the preparation and infusion of patisiran.
Vutrisiran: Dyspnea
Standard response letter on vutrisiran and the adverse event of dyspnea.
Standard response letter on vutrisiran and the adverse event of dyspnea.
Patisiran: Blood Brain Barrier
Standard response letter containing pre-clinical data on the tissue distribution of patisiran.
Standard response letter containing pre-clinical data on the tissue distribution of patisiran.
Zilebesiran: KARDIA-3 Study
Standard response letter on zilebesiran and the KARDIA-3 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran in patients with high CV risk and hypertension that is not adequately controlled with at least 2 standard-of-care antihypertensives.
Standard response letter on zilebesiran and the KARDIA-3 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran in patients with high CV risk and hypertension that is not adequately controlled with at least 2 standard-of-care antihypertensives.